Entrada Therapeutics Inc TRDA
$7.57 $0.03 (0.39%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
TRDA Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Entrada Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Entrada Therapeutics Inc. Stock Analysis TRDA
United States Health Care Micro Cap Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company is headquartered in Boston, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2021-10-29. The firm is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The firm is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The firm is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The firm has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Entrada Therapeutics Inc (TRDA) Chart
Financial Metrics & Statements of Entrada Therapeutics Inc (TRDA)
FAQ's for Entrada Therapeutics Inc (TRDA)
- As of August 2026, Entrada Therapeutics Inc TRDA is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Entrada Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Entrada Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Entrada Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Entrada Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Entrada Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Entrada Therapeutics Inc (TRDA)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
